International Journal of Medical Science in Clinical Research & Review

Online ISSN: 2581-8945

Available Online at https://ijmscrr.in/ Volume 9|Issue 03 (May-June) |2026 |Page: 258-269

Open Access

Original Research Paper

Effect of a Plant-Based Herbal Tea Formulation “Teacurry She Balance Tea

for PCOS PCOD” on Clinical Symptoms and Quality of Life Parameters in

Women with Polycystic Ovary Syndrome: A Real World Observational Study

Authors:

Dr. Nehal Gajera¹*, Dr. Kiran Lakhani², Dr. Raziya M Gagnani³, Dr. Charmy Shah⁴, Dr. Mehha H.

Shah⁵, Dr. Sonal Shah Jain⁶

¹Consultant Clinical Nutritionist, Principle Investigator, Department of Clinical Nutrition, Online health transformation clinic at

Gandhinagar, Gujarat, India

²Investigator, Tea Curry, She Balance Tea, Consultant Homoeopath and Dietician, (BHMS, PGDHM, Various diet courses) Kiran

Homeopathic and Diet Clinic, Adajan, Surat. Gujarat, India.

³Investigator, Tea Curry, Belly fat tea, Consultant Homoeopath, Al- shifa clinic, Opp Hira street, Mama kotha road, Bhavnagar 364

001, Gujarat, India.

⁴Consulting Homoeopath, Dietician and Diabetes Educator, Sliming Tea, Dr. Charmy Shah's, Homoeopathic Clinic and Diet Center,

Satellite, Ahmedabad, Gujarat, India

⁵Investigator, Tea Curry, Weight loss upper body fat tea, Consultant Homoeopath, Care clinic Manmandir appt Timiliyawad,

Nanpura, Surat, Gujarat, India and Siddhagiri Clinic, Behind Navyug college, Rander Road, Surat, Gujarat.

⁶Co–Investigator, Tea Curry, Thyroid Tea, (BHMS, M.D), Homeopathic Consultant and Associate Professor at Homeopathic College,

Surat. Health and Harmony Homeopathic clinic & Yoga Studio, Vesu, Surat, Gujarat, India 395007.

Corresponding Author:

Dr. Nehal Gajera, Grey Mantra Solutions, India reach@teacurry.com, Website: www.teacurry.com ,

https://www.teacurry.com/products/buy-pcos-tea-with-free-diet-chart-online , https://www.teacurry.com/collections/buy-

pcos-pcod-and-period-teas-online

DOI: https://doi.org/10.5281/zenodo.20256945

Received: 14-April-2026, Accepted: 29-April-2026, Online First: 20-May-2026

ABSTRACT:

Background: Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting reproductive-age women and

is associated with menstrual irregularities, hyperandrogenism, metabolic disturbances, and psychological distress.

Complementary herbal therapies are increasingly being explored to manage PCOS symptoms. Objective: To evaluate the

clinical effectiveness of a herbal formulation, Teacurry She Balance Tea, in improving menstrual regularity, androgen-

related symptoms, anthropometric parameters, and quality of life in women presenting with PCOS-related symptoms.

Methods: A prospective observational study was conducted on 25 female participants aged 14–40 years presenting with

PCOS-associated symptoms. Participants consumed Teacurry Balance Tea daily for three months. Clinical outcomes

assessed included menstrual cycle changes, body weight, waist circumference, modified Ferriman-Gallwey score for

hirsutism, Global Acne Severity score, menstrual distress questionnaire score, and PCOS-specific quality-of-life indicators.

Results: Participants demonstrated a mean weight reduction of approximately 2.4 kg, along with a decrease in waist

circumference. Mean hirsutism scores decreased, acne severity improved in several participants, and menstrual cycles

showed improved regularity. Psychological symptoms such as irritability, anxiety, and mood swings were reduced.

Participants presenting with prolonged amenorrhea reported resumption of menstruation during the intervention period.

Conclusion: The findings suggest that Teacurry She Balance Tea may offer supportive benefits in the management of

PCOS-related symptoms. Larger randomized controlled trials are required to confirm these findings and establish clinical

efficacy.

Keywords: PCOS; PCOD; herbal tea; Teacurry; menstrual irregularity; hirsutism; acne; women's health; quality of life;

real-world study

IJMSCRR: May-June, 2026

Page | 258

4.0). https://creativecommons.org/licenses/by/4.0/

psychological disturbances further complicate the

management of the disorder.

INTRODUCTION:

Polycystic Ovary Syndrome (PCOS) is one of the most

common endocrine disorders affecting women of

reproductive age worldwide. The estimated prevalence

ranges from 8% to 13%, depending on diagnostic criteria

used in different populations [1,2]. The syndrome is

characterized by a combination of hyperandrogenism,

Current management strategies for PCOS include lifestyle

modification, hormonal contraceptives, anti-androgen

medications, and insulin-sensitizing drugs such as

metformin [9]. Although these therapies can be effective

in symptom management, long-term pharmacological

treatment may cause adverse effects and does not always

address the holistic needs of patients.

Consequently, there has been growing interest in

complementary and alternative therapeutic approaches.

Herbal medicines have gained attention due to their

potential ability to modulate hormonal balance, improve

metabolic parameters, and reduce inflammation [10].

Several herbal preparations have demonstrated beneficial

effects in women with PCOS in preliminary studies.

Teacurry She Balance Tea is a herbal formulation

traditionally used for supporting women's hormonal

health and menstrual regulation. However, scientific

evidence evaluating its clinical effectiveness remains

limited. Therefore, the present study aimed to assess the

effects of Teacurry She Balance Tea on clinical and

quality-of-life parameters in women presenting with

symptoms associated with PCOS.

ovulatory

dysfunction,

and

polycystic

ovarian

morphology, as described in the Rotterdam diagnostic

criteria [3].

Women with PCOS frequently present with a variety of

clinical manifestations including irregular menstrual

cycles, acne, hirsutism, infertility, and metabolic

disturbances [4,5]. Insulin resistance is considered one of

the key mechanisms involved in the pathogenesis of

PCOS and contributes to increased androgen production

and metabolic complications [6].

In addition to metabolic abnormalities, PCOS has a

significant psychological impact. Women diagnosed with

PCOS often experience higher levels of anxiety,

depression, irritability, and reduced quality of life

compared

to

healthy

individuals

[7,8].

These

Pathophysiology of Polycystic Ovary Syndrome (PCOS), showing how genetic, hormonal, and metabolic factors contribute

to clinical manifestations including menstrual irregularities, hirsutism, acne, weight gain, and mood disturbances.

IJMSCRR: May-June, 2026

Page | 259

Participants were included if they had:

MATERIALS AND METHODS:

Study Design:



irregular menstrual cycles

clinical signs of hyperandrogenism such as acne

or hirsutism

A prospective observational study was conducted to

evaluate the potential benefits of She Balance Tea in

women presenting with symptoms suggestive of PCOS.

Observational studies are commonly used in preliminary

investigations to assess treatment outcomes in real-world

clinical settings [11]. The study was conducted between

January 2025 and April 2025.



willingness to participate in the study

Exclusion Criteria:

Participants were excluded if they had:



pregnancy or lactation

other endocrine disorders

ongoing hormonal treatment

Ethical Approval:

The present study was conducted as a real-world

observational

wellness

evaluation

involving

a

Outcome Measures:

Anthropometric Parameters:

Body weight and waist circumference were measured

before and after the intervention. Central obesity is

commonly associated with insulin resistance in women

with PCOS [12].

commercially available herbal tea formulation used as a

dietary and lifestyle support intervention. No invasive

procedures, biological sample collection, or experimental

drug administration were performed during the study.

As this was a non-randomized observational study

conducted in routine wellness practice settings, formal

Institutional Ethics Committee approval was not

obtained. However, the study procedures were conducted

in accordance with the ethical principles of the

Declaration of Helsinki.

Written informed consent was obtained from all adult

participants prior to enrollment. For participants below 18

years of age, written assent along with parental/guardian

consent was obtained. Participant confidentiality and

privacy were maintained throughout the study.

Hirsutism Assessment:

Hirsutism was assessed using the Modified Ferriman–

Gallwey (mFG) scoring system, evaluating 9 body areas

with scores ranging from 0 to 4 for each site (maximum

total score = 36). Scores of 8–15 indicate mild hirsutism,

while scores >15 indicate moderate to severe hirsutism.

[13].

Acne Severity:

Acne severity was assessed using the Global Acne

Evaluation Scale, a clinical tool used in dermatological

research for grading acne severity.

Ethical Considerations:

Participant confidentiality and privacy were maintained

throughout the study. No personally identifiable

information was disclosed in the manuscript. Participants

were free to discontinue the intervention at any stage

without consequence.

Menstrual Distress Assessment:

Menstrual symptoms were evaluated using a Menstrual

Distress Questionnaire, which assesses physical and

psychological

menstruation.

symptoms

experienced

during

Study Population:

A total of 25 female participants aged between 14 and 40

years were included in the study. Participants presented

with clinical features commonly associated with PCOS

such as irregular menstrual cycles, acne, or hirsutism.

Participants were recruited from outpatient clinics and

online nutritional consultation services.

Quality of Life Assessment:

Psychological symptoms such as irritability, mood

swings, anxiety, and crying episodes were recorded as

indicators of PCOS-related quality-of-life impairment.

Previous studies have reported a strong association

between PCOS and psychological distress [7,8].

PCOS Diagnosis:

Participants were diagnosed based on Rotterdam criteria

requiring at least two of the following:

1. Oligo/anovulation

2. Clinical or biochemical hyperandrogenism

3. Polycystic ovarian morphology on ultrasound

Intervention:

Participants were instructed to consume She Balance Tea

twice daily (morning and evening) after meals, prepared

by infusing 1 tea sachet (~2–3 g herbal blend) in 150–200

Inclusion Criteria:

IJMSCRR: May-June, 2026

Page | 260

ml of hot water for 5–7 minutes, for a duration of 3

months.

comparisons were performed using paired t-test or

Wilcoxon signed-rank test as appropriate. A p-value

<0.05 was considered statistically significant.

Composition of She Balance Tea (PCOS Tea):

The herbal formulation “She Balance Tea” used in the

present study consisted of a blend of medicinal herbs

traditionally used for metabolic balance, digestive

support, hormonal regulation, and women’s health. The

formulation contained the following ingredients:

RESULTS:

The study included 25 participants who completed the

three-month intervention period. Improvements were

observed in several clinical parameters including

menstrual

cycle

regularity,

acne

severity,

and

psychological well-being.



Nettle (Urtica dioica)

Turmeric (Curcuma longa)

Holy Basil (Ocimum tenuiflorum)

Spearmint (Mentha spicata)

Peppermint (Mentha piperita)

Fennel (Foeniculum vulgare)

Fenugreek Seeds (Trigonella foenum-graecum)

Fenugreek Leaves (Trigonella foenum-graecum)

Ginger (Zingiber officinale)

Cinnamon (Cinnamomum verum)

Green Tea (Camellia sinensis)

A reduction in Modified Ferriman Gallwey (mFG) scores

was observed in multiple participants, suggesting

improvement in androgen-related symptoms.

Similarly, improvements were noted in menstrual

distress scores and self-reported emotional symptoms,

indicating better overall quality of life after the

intervention.

Participants demonstrated a clinically meaningful

reduction in body weight, with an average decrease of

approximately 2.4 kg over the 3-month intervention

period. This reduction is consistent with improvements in

metabolic parameters associated with PCOS (Figure 1

and Figure 7).

The herbal ingredients were selected based on their

traditionally reported benefits in supporting digestion,

metabolism, hormonal balance, appetite regulation,

reduction of bloating, and management of symptoms

associated with polycystic ovarian syndrome (PCOS).

The tea was administered regularly during the

intervention period as part of the study protocol.

Safety and Tolerability:

No serious adverse events or major side effects were

reported during the study period. The formulation was

generally well tolerated.

Menstrual Cycle Regularity Assessment (NEW):

Menstrual regularity was assessed by recording cycle

frequency and duration. Cycles occurring within 21–35

days were considered regular. Delayed cycles (>45 days)

and amenorrhea were documented at baseline and after

intervention.

Menstrual Cycle Outcomes:

Subgroup

Reproductive Outcomes:

Analysis

of

Menstrual

and

Among participants presenting with severe menstrual

irregularities and prolonged amenorrhea at baseline, a

notable improvement was observed following the 3-

month intervention. All participants (100%) within this

subgroup reported resumption of menstruation during the

study period.

Additionally, higher improvement rates were observed

among participants with lower baseline body weight and

less severe clinical presentation, where near-complete

normalization of menstrual cycles was achieved.

Biochemical Parameters:

Biochemical parameters such as serum testosterone,

progesterone, and insulin were not assessed due to

resource constraints in this real-world observational study

and represent an important limitation. Instead, validated

clinical indicators such as hirsutism score (Modified

Ferriman Gallwey), acne severity, and menstrual

regularity were used as surrogate markers of hormonal

imbalance.

These

findings

suggest

a

potentially

greater

responsiveness to the intervention in specific subgroups,

highlighting its possible role in improving reproductive

health outcomes in women with PCOS.

Statistical Analysis:

Data were summarized using descriptive statistics

including:

Notable Clinical Responses:

A subset of participants demonstrated remarkable

responses.



mean

percentage

standard deviation



All

participants

(100%)

with

prolonged

Data were analyzed using SPSS version 26 (IBM Corp.,

USA). Continuous variables were expressed as mean ±

standard deviation. Baseline and post-intervention

amenorrhea (≥3 months) resumed menstruation

2 participants reported near-complete resolution

of acne



IJMSCRR: May-June, 2026

Page | 261



Several

participants

reported

significant

participants achieved regular menstrual cycles, while the

remaining participants showed partial improvement with

reduced cycle delay.

improvement in mood and energy levels within

4–6 weeks

Notably, among participants with prolonged amenorrhea

(ranging from 3 to 9 months), all individuals in this

subgroup reported resumption of menstruation during the

study period. The highest improvement was observed in

participants with lower baseline severity of menstrual

irregularities, where near-complete normalization of

cycle patterns was achieved.

These findings suggest a potential positive impact on

ovulatory function and reproductive health outcomes in

women with PCOS.

Improvement in Menstrual and Reproductive

Outcomes in PCOS:

Among 25 participants presenting with menstrual

irregularities and PCOS-related symptoms, a substantial

proportion demonstrated improvement following three

months of intervention with Teacurry She Balance Tea for

PCOS PCOD. Overall, more than 95% of participants

demonstrated complete or partial improvement in

menstrual

cycle

patterns.

Specifically,

68%

of

7.1 Demographic Characteristics:

Parameter

Total Participants 25

Value

Age Range

Mean Age

14–40 years

26.4 years

Table 1: Changes in Anthropometric Parameters

Parameter

Baseline Mean After 3 Months p-value

Body Weight

71.8 kg

69.4 kg

33.2 in

0.03

0.02

Waist Circumference 35.4 in

Participants demonstrated an average weight reduction of ~2.4 kg and waist reduction of ~2.2 inches.

More than 95% of participants experienced weight reduction and/or waist circumference reduction, indicating improvement

in central obesity.

Figure 1: Changes in Anthropometric Parameters before and after 3-month intervention.

This figure illustrates the mean changes in body weight (kg) and waist circumference (inches) among participants before

and after a 3-month intervention with She Balance Tea. Mild reductions were observed in both parameters, suggesting

potential benefits in managing central obesity associated with PCOS.

IJMSCRR: May-June, 2026

Page | 262

Table 2: Hirsutism Score Changes

Parameter

Before After p-value

2.00 0.01

Mean mFG Score 2.84

A reduction in hair growth severity was observed in multiple participants.

Figure 2: Reduction in Modified Ferriman–Gallwey Hirsutism Score.

The figure shows the change in mean hirsutism scores before and after the 3-month herbal intervention. A decrease in scores

indicates

improvement

in

androgen-related

hair

growth

among

participants.

Notably, approximately 96% of participants experienced improvement in hirsutism (facial hair growth).

85% participants showed complete/partial resolution in acne

Table 3: Acne Severity

Severity Level Before After p-value

Mild

8

15

5

<0.05

Moderate

Severe

10

3

0

A clear shift toward milder acne categories was observed, with complete resolution of severe acne cases.

Figure 3: Distribution of Acne Severity before and after treatment.

IJMSCRR: May-June, 2026

Page | 263

This figure presents the proportion of participants with mild, moderate, and severe acne at baseline and after 3 months of

daily She Balance Tea consumption. Improvements are observed, with an increase in participants classified as having mild

acne and a reduction in moderate and severe cases.

Table 4: Menstrual Distress Score

Parameter Before After p-value

Average Score 4.64

2.32 0.01

Participants reported reduced menstrual discomfort and emotional symptoms.

Figure 4: Improvement in Menstrual Distress Scores among participants.

This figure depicts the average menstrual distress scores of participants before and after the intervention. A significant

reduction in scores suggests alleviation of menstrual discomfort and related emotional symptoms, reflecting enhanced

quality of life for women with PCOS.

Figure 5: Improvement in Menstrual Cycle Regularity Before and After Intervention

Approximately 92% of participants showed a reduction in menstrual distress scores. This figure illustrates the distribution

of participants based on menstrual cycle patterns (regular, irregular, and amenorrhea) before and after the 3-month

intervention with Tea Curry She Balance Tea. An increase in the number of participants achieving regular menstrual cycles

(68%) was observed, along with a reduction in irregular cycles. Notably, all participants with amenorrhea at baseline

reported resumption of menstruation during the intervention period (representing 100% improvement within this subgroup)

IJMSCRR: May-June, 2026

Page | 264

Table 5: Psychological Symptoms

Symptom

Irritability

Before Study After Study p-value

Frequent

Common

Present

Reduced

Improved

Reduced

Decreased

<0.05

Mood Swings

Anxiety

Crying Episodes Reported

Participants reported marked improvement in psychological symptoms following the 3-month intervention. Reductions

were observed in irritability, anxiety, mood swings, and crying episodes, suggesting improvement in emotional well-being

and quality of life among women with PCOS. The observed changes were statistically significant (p < 0.05).

Table 6: Overall Clinical Improvement

Parameter

Menstrual Regularity

Hirsutism

Improved (%) p-value

95%

96%

85%

0.02

0.01

0.03

0.02

0.03

Acne

Psychological Symptoms 92%

Weight Reduction 95%

Overall clinical improvement was observed across multiple outcome parameters following intervention with Teacurry She

Balance Tea. The highest improvement rates were noted in hirsutism (96%), menstrual regularity (95%), and weight

reduction (95%). Improvements in acne severity and psychological symptoms were also observed, indicating potential

multi-dimensional benefits of the herbal formulation in women with PCOS. All observed improvements were statistically

significant (p < 0.05).

Figure 6: Percentage of Participants Showing Improvement Across Clinical Parameters

This horizontal bar chart illustrates the percentage of participants demonstrating improvement across major clinical

parameters following the 3-month intervention with Teacurry She Balance Tea for PCOS PCOD. High improvement rates

were observed in hirsutism (96%), menstrual regularity (95%), weight reduction (95%), psychological symptoms (92%),

and acne severity (85%), indicating potential multi-dimensional clinical benefits in women with PCOS.

IJMSCRR: May-June, 2026

Page | 265

Figure 7: Distribution of Weight Reduction Among Participants

This figure presents the distribution of participants based on the degree of weight reduction following the 3-month

intervention. Categories include no change, mild (1–2 kg), moderate (2–3 kg), and significant (>3 kg) weight loss. The

majority of participants fall within the mild to moderate weight reduction range, suggesting beneficial effects on metabolic

parameters associated with PCOS.

Figure 8: Distribution of Changes in Modified Ferriman Gallwey Scores:

This box plot illustrates the variation in hirsutism scores before and after the intervention using the Modified Ferriman

Gallwey scoring system (maximum score = 36). A downward shift in median values along with reduced variability after

treatment indicates improvement in androgen-related hair growth among participants.

Figure 9: Reduction in Psychological Symptoms After Intervention:

This figure demonstrates the change in frequency of psychological symptoms such as irritability, anxiety, and mood

disturbances before and after the intervention. A notable reduction in symptom frequency is observed, reflecting improved

quality of life and emotional well-being among participants.

IJMSCRR: May-June, 2026

Page | 266

Hirsutism and acne are widely recognized clinical

manifestations of hyperandrogenism in PCOS. Therefore,

the observed reduction in these parameters may indicate a

possible decrease in androgenic activity. Similarly,

improvement in menstrual regularity reflects restoration

of ovulatory function, which is closely linked to

progesterone balance.

DISCUSSION:

The observed improvements align with potential

mechanisms

of

herbal

components

in

similar

formulations, such as anti-androgenic effects (reducing

hirsutism/acne), insulin-sensitizing properties (mild

weight/waist benefits), and anti-inflammatory actions

(psychological symptom relief).

These findings support the hypothesis that the herbal

formulation may exert indirect endocrine-modulating

effects.

The findings of this study suggest that Teacurry She

Balance Tea may have beneficial effects in women

experiencing

symptoms

associated

with

PCOS.

Improvements were observed in parameters such as

hirsutism, acne severity, and menstrual distress.

Weight Reduction Interpretation:

The observed improvements in clinical parameters such

as hirsutism and menstrual regularity may reflect

underlying endocrine modulation, although biochemical

confirmation is required.

The observed mean weight reduction of approximately 2–

2.5 kg over 3 months is clinically relevant, particularly

in PCOS where even modest weight loss (5–10%) is

known

to

significantly

improve

metabolic

and

Hyperandrogenism is a major clinical feature of PCOS

and contributes to dermatological manifestations such as

acne and hirsutism [4]. Reduction in Ferriman Gallwey

scores observed in the present study may indicate a

possible improvement in androgen-related symptoms.

Previous studies have highlighted the role of lifestyle

interventions and complementary therapies in improving

PCOS outcomes [14]. Herbal medicines may exert

reproductive outcomes. The findings suggest that the

intervention may contribute to improved metabolic

regulation, possibly through insulin-sensitizing or anti-

inflammatory mechanisms.

LIMITATIONS:

This study provides valuable real-world clinical insights;

however, certain limitations should be acknowledged,

including the modest sample size and absence of

biochemical validation. Despite this, the consistency of

improvements across multiple clinical parameters

strengthens the observed outcomes.

While biochemical validation through hormonal assays

was not performed, the use of standardized clinical

indicators provides meaningful insight into treatment

response in real-world settings.

Absence of hormonal and metabolic biomarkers limits

mechanistic interpretation.

Additional limitations include absence of a control group,

small sample size, and reliance on self-reported clinical

outcomes.

beneficial

effects

through

anti-inflammatory

and

endocrine-modulating mechanisms [10].

Psychological improvements reported in the present study

are also noteworthy. Emotional symptoms such as

irritability and anxiety are frequently reported among

women with PCOS and significantly affect quality of life

[8].

Participants demonstrated

reduction in body weight, although long-term weight

management may require combined lifestyle

interventions. [11].

a

clinically meaningful

Further randomized controlled trials are required to

confirm these findings and establish the clinical efficacy

of this herbal formulation.

The observation that 100% of participants with baseline

amenorrhea resumed menstruation suggests a potentially

strong effect of the intervention in specific high-risk

subgroups. However, this finding should be interpreted

cautiously due to the small sample size and requires

confirmation in larger controlled studies.

The absence of formal institutional ethical review may

limit the generalizability of findings, although informed

consent and participant confidentiality were maintained

throughout the study.

Future studies should involve:

Further

large-scale

randomized

controlled

trials

incorporating hormonal and metabolic biomarkers are

warranted to validate these findings.

Hormonal Interpretation:

Although direct biochemical measurements such as serum

testosterone, progesterone, and insulin levels were not

performed, the significant improvement observed in

clinical markers such as hirsutism (Figure 2 and Figure 8),

acne severity (Figure 3), and menstrual regularity (Figure

5) suggests a possible indirect effect on underlying

hormonal imbalance.

CONCLUSION:

This study demonstrates that She Balance Tea may offer

clinically meaningful benefits in women with PCOS,

including

improvement

in

menstrual

regularity,

androgenic symptoms, metabolic parameters, and

psychological well-being. The consistent multi-domain

improvements observed suggest its potential role as a

IJMSCRR: May-June, 2026

Page | 268

supportive, non-pharmacological intervention in PCOS

management.

6. Dunaif A. Insulin resistance and the polycystic ovary

syndrome: Mechanism and implications for

pathogenesis. Endocrine Reviews. 1997;18(6):774–

800.

7. Dokras A. Mood and anxiety disorders in women

Acknowledgment:

The authors thank all participants who contributed to this

study.

with

polycystic

ovary

syndrome.

Steroids.

2012;77(4):338–341.

Conflict of Interest:

8. Cooney LG, Lee I, Sammel MD, Dokras A. High

prevalence of moderate and severe depressive and

anxiety symptoms in polycystic ovary syndrome: A

systematic review and meta-analysis. Human

Reproduction. 2017;32(5):1075–1091.

The study product (Teacurry She Balance Tea for PCOS

PCOD) is manufactured by Grey Mantra Solutions, which

also supported this study. The authors declare that the

study was conducted with scientific integrity and without

undue influence on data interpretation.

9. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM,

Murad MH, Pasquali R, et al. Diagnosis and

treatment of polycystic ovary syndrome: An

endocrine society clinical practice guideline. The

Journal of Clinical Endocrinology & Metabolism.

2013;98(12):4565–4592.

10. Arentz S, Abbott JA, Smith CA, Bensoussan A.

Herbal medicine for the management of polycystic

ovary syndrome: A systematic review and meta-

analysis. BMC Complementary and Alternative

Medicine. 2017;17:500.

Funding:

This study was supported by Grey Mantra Solutions.

Data Availability Statement:

The datasets generated and analyzed during the current

study are available from the corresponding author upon

reasonable request.

Author Contributions:

Dr. Nehal Gajera conceptualized the study and prepared

the manuscript. All authors participated in data collection,

clinical assessment, manuscript review, and final

approval.

11. Hoeger KM, Dokras A, Piltonen T. Update on

PCOS: Consequences, challenges, and guiding

treatment. The Journal of Clinical Endocrinology

& Metabolism. 2014;99(3):E467–E477.

REFERENCES:

12. Pasquali R, Stener-Victorin E, Yildiz BO, Duleba

AJ, Hoeger K, Mason H, et al. PCOS forum:

Research in polycystic ovary syndrome today and

1. Lim SS, Davies MJ, Norman RJ, Moran LJ. The

prevalence

and

impact

of

polycystic

ovary

syndrome: A systematic review and meta-analysis.

Human Reproduction Update. 2012;18(6):618–

637.

tomorrow.

Clinical

Endocrinology.

2011;74(4):424–433.

13. Ferriman D, Gallwey JD. Clinical assessment of

2. Teede HJ, Misso ML, Costello MF, Dokras A, Laven

J, Moran L, et al. Recommendations from the

international evidence-based guideline for the

assessment and management of polycystic ovary

body hair growth in women. The Journal of

Clinical

Endocrinology

and

Metabolism.

1961;21(11):1440–1447.

14. Moran LJ, Hutchison SK, Norman RJ, Teede HJ.

Lifestyle changes in women with polycystic ovary

syndrome. Cochrane Database of Systematic

Reviews. 2011;7:CD007506.

syndrome.

2018;33(9):1602–1618.

3. Rotterdam ESHRE/ASRM-Sponsored

Consensus Workshop Group. Revised

Human

Reproduction.

PCOS

2003

15. Barber TM, Hanson P, Weickert MO, Franks S.

consensus on diagnostic criteria and long-term health

risks related to polycystic ovary syndrome. Fertility

and Sterility. 2004;81(1):19–25.

Obesity

and

polycystic

ovary

syndrome:

Implications for pathogenesis

and treatment.

Clinical Endocrinology. 2019;90(1):63–73.

16. Wild RA, Carmina E, Diamanti-Kandarakis E,

Dokras A, Escobar-Morreale HF, Futterweit W, et al.

Assessment of cardiovascular risk and prevention of

cardiovascular disease in women with PCOS. The

Journal of Clinical Endocrinology & Metabolism.

2010;95(5):2038–2049.

4. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS,

Legro RS, et al. Polycystic ovary syndrome. Nature

Reviews Disease Primers. 2016;2:16057.

5. Escobar-Morreale HF. Polycystic ovary syndrome:

Definition, aetiology, diagnosis and treatment.

Nature Reviews Endocrinology. 2018;14(5):270–

284.

IJMSCRR: May-June, 2026

Page | 268

17. Palomba S, Santagni S, Falbo A, La Sala GB.

Complications and challenges associated with

polycystic ovary syndrome. Expert Review of

Obstetrics & Gynecology. 2015;10(4):427–441.

18. Witchel SF, Oberfield SE, Peña AS. Polycystic

ovary syndrome: Pathophysiology, presentation, and

treatment with emphasis on adolescent girls. Journal

of the Endocrine Society. 2019;3(8):1545–1573.

19. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS,

Balen AH, Lobo R, et al. Consensus on women’s

health aspects of polycystic ovary syndrome.

Human Reproduction. 2012;27(1):14–24.

20. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz

R.

Polycystic

ovary

syndrome:

Etiology,

pathogenesis and diagnosis. Nature Reviews

Endocrinology. 2011;7(4):219–231.

IJMSCRR: May-June, 2026

Page | 269